Trimester-Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study. [PDF]
Yang L +8 more
europepmc +1 more source
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004-2022. [PDF]
Nakahata Y +5 more
europepmc +1 more source
Health‐Related Quality of Life in Rare Forms of Childhood‐Onset Hereditary Spastic Paraplegia
ABSTRACT We assessed health‐related quality of life (HRQoL) in 80 children with rare hereditary spastic paraplegias using the Caregiver Priorities and Child Health Index of Life with Disabilities and clinician‐reported outcomes. HRQoL was consistently reduced, particularly in relation to motor, autonomic, and bulbar symptoms.
Henri J. D. Schmidt +11 more
wiley +1 more source
Letter to the Editor: Detrimental effects of diabetes mellitus in alcoholic liver disease. [PDF]
Akbar Syed MA +7 more
europepmc +1 more source
Hepcidin in morbidly obese women with non-alcoholic fatty liver disease
Teresa Auguet +10 more
openalex +2 more sources
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Response: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease (J Obes Metab Syndr 2024;33:222-8). [PDF]
Roy A, Goenka MK.
europepmc +1 more source

